1. Home
  2. VWAV vs CRBU Comparison

VWAV vs CRBU Comparison

Compare VWAV & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VWAV

VisionWave Holdings Inc.

HOLD

Current Price

$2.93

Market Cap

139.7M

Sector

Technology

ML Signal

HOLD

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$1.59

Market Cap

166.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VWAV
CRBU
Founded
2024
2011
Country
United States
United States
Employees
12
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.7M
166.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
VWAV
CRBU
Price
$2.93
$1.59
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
562.1K
2.4M
Earning Date
05-18-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.64
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.63
Revenue Next Year
N/A
$10.93
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.13
$1.38
52 Week High
$15.80
$3.53

Technical Indicators

Market Signals
Indicator
VWAV
CRBU
Relative Strength Index (RSI) 30.82 35.14
Support Level N/A $1.39
Resistance Level $6.64 $1.73
Average True Range (ATR) 0.34 0.11
MACD -0.07 -0.01
Stochastic Oscillator 0.64 0.94

Price Performance

Historical Comparison
VWAV
CRBU

About VWAV VisionWave Holdings Inc.

VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Share on Social Networks: